{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:49:17Z","timestamp":1793713757227,"version":"4.6.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["LXH254"],"award-info":[{"award-number":["LXH254"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.lungcan.2024.107964","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T12:29:03Z","timestamp":1727353743000},"page":"107964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer"],"prefix":"10.1016","volume":"197","author":[{"given":"David","family":"Planchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0404-7741","authenticated-orcid":false,"given":"Martin","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wermke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Heist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae","family":"Min Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8190-499X","authenticated-orcid":false,"given":"Noemi","family":"Reguart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7295-6074","authenticated-orcid":false,"given":"Miguel F.","family":"Sanmamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5899-6125","authenticated-orcid":false,"given":"Pilar","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Bootle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu\u00e2n-Mai","family":"Couillebault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2560-8488","authenticated-orcid":false,"given":"Teresa","family":"Poggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2241-5066","authenticated-orcid":false,"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Moschetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7324-7977","authenticated-orcid":false,"given":"Christophe","family":"Dooms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2024.107964_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107964_b0010","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.lungcan.2024.107964_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.823618","article-title":"Immunotherapy in lung cancer: current landscape and future directions","volume":"13","author":"Mamdani","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107964_b0020","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J Clin Oncol"},{"issue":"12","key":"10.1016\/j.lungcan.2024.107964_b0025","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/1535-7163.MCT-21-0201","article-title":"Characterization of KRAS mutation subtypes in non-small cell lung cancer","volume":"20","author":"Judd","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.lungcan.2024.107964_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051321","article-title":"Direct targeting KRAS mutation in non-small cell lung cancer: focus on resistance","volume":"14","author":"Reita","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.lungcan.2024.107964_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205059","article-title":"Progress on Ras\/MAPK signaling research and targeting in blood and solid cancers","volume":"13","author":"Dillon","year":"2021","journal-title":"Cancers (basel)"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107964_b0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/bjc.2017.399","article-title":"Targeting the Raf kinases in human cancer: The Raf dimer dilemma","volume":"118","author":"Durrant","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2024.107964_b0045","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/JTO.0000000000000644","article-title":"BRAF alterations as therapeutic targets in non-small-cell lung cancer","volume":"10","author":"Nguyen-Ngoc","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107964_b0050","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.21037\/tlcr.2019.10.22","article-title":"Targeting BRAF mutations in non-small cell lung cancer","volume":"8","author":"O\u2019Leary","year":"2019","journal-title":"Transl Lung Cancer Res"},{"issue":"7","key":"10.1016\/j.lungcan.2024.107964_b0055","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107964_b0060","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2024.107964_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123608","article-title":"Efficacy of dabrafenib plus trametinib combination in patients with BRAF V600E-mutant NSCLC in real-world setting: GFPC 01-2019","volume":"12","author":"Auliac","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.lungcan.2024.107964_b0070","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, open-label study of encorafenib plus binimetinib in patients with BRAF(V600)-mutant metastatic non-small-cell lung cancer","volume":"41","author":"Riely","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107964_b0075","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","article-title":"Targeting the MAPK pathway in KRAS-driven tumors","volume":"37","author":"Drosten","year":"2020","journal-title":"Cancer Cell"},{"issue":"7287","key":"10.1016\/j.lungcan.2024.107964_b0080","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107964_b0085","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.lungcan.2024.107964_b0090","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1158\/1078-0432.CCR-20-2563","article-title":"LXH254, a potent and selective ARAF-sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors","volume":"27","author":"Monaco","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.lungcan.2024.107964_b0095","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.22.02018","article-title":"Initial evidence for the efficacy of naporafenib in combination with trametinib in NRAS-mutant melanoma: results from the expansion arm of a phase Ib, open-label study","volume":"41","author":"de Braud","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lungcan.2024.107964_b0100","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/carcin\/bgq020","article-title":"Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells","volume":"31","author":"Zhang","year":"2010","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107964_b0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41698-018-0051-4","article-title":"A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types","volume":"2","author":"Wagle","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.lungcan.2024.107964_b0110","doi-asserted-by":"crossref","unstructured":"K. Schad, K. Baumann Conzett, M.C. Zipser, V. Enderlin, J. Kamarashev, L.E. French, R. Dummer, Mitogen-activated protein\/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders, Clin Cancer Res 16(3) (2010) 1058-1064, 10.1158\/1078-0432.CCR-09-1766.","DOI":"10.1158\/1078-0432.CCR-09-1766"},{"issue":"36","key":"10.1016\/j.lungcan.2024.107964_b0115","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107964_b0120","article-title":"The long half-life of programmed cell death protein 1 inhibitors may increase the frequency of immune-related adverse events after subsequent EGFR tyrosine kinase inhibitor therapy","volume":"1","author":"Shinno","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2024.107964_b0125","doi-asserted-by":"crossref","first-page":"113458","DOI":"10.1016\/j.ejca.2023.113458","article-title":"First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations","volume":"196","author":"Janku","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"19","key":"10.1016\/j.lungcan.2024.107964_b0130","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.18632\/oncotarget.26753","article-title":"Biomarker results from a phase II study of MEK1\/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma","volume":"10","author":"van Herpen","year":"2019","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.lungcan.2024.107964_b0135","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2024.107964_b0140","unstructured":"ClinicalTrials.gov. A study to assess naporafenib (ERAS-254) administered with trametinib in patients with RAS Q61X mutations (SEACRAFT-1). https:\/\/clinicaltrials.gov\/study\/NCT05907304?intr=Naporafenib&rank=1. Accessed December 2023."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107964_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01025-7","article-title":"MEK inhibitors for the treatment of non-small cell lung cancer","volume":"14","author":"Han","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107964_b0150","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"suppl 2","key":"10.1016\/j.lungcan.2024.107964_b0155","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/j.annonc.2023.09.1838","article-title":"652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)","volume":"34","author":"Arbour","year":"2023","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107964_b0160","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4143\/crt.2022.078","article-title":"Challenges in the use of targeted therapies in non-small cell lung cancer","volume":"54","author":"Rivera-Concepcion","year":"2022","journal-title":"Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107964_b0165","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.gendis.2022.05.006","article-title":"Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: current status in clinical trials","volume":"10","author":"Song","year":"2023","journal-title":"Genes Dis"},{"issue":"3","key":"10.1016\/j.lungcan.2024.107964_b0170","first-page":"3233","article-title":"Prognostic value of KRAS\/TP53\/PIK3CA in non-small cell lung cancer","volume":"17","author":"Zhao","year":"2019","journal-title":"Oncol. Lett."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224004987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224004987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:06:20Z","timestamp":1777518380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224004987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":34,"alternative-id":["S0169500224004987"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107964","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107964"}}